← Back to Anthem Biosciences Ltd. overview
Anthem Biosciences Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,845 cr | ₹451 cr | ₹8.04 | ₹2,808 cr | ₹2,410 cr | 18.73% | 26.43% | 0.05x | 24.46% |
| FY2024 | ₹1,419 cr | ₹367 cr | ₹6.54 | ₹2,398 cr | ₹1,925 cr | 19.08% | 22.49% | 0.12x | 25.88% |
| FY2023 | ₹1,057 cr | ₹385 cr | ₹6.86 | ₹2,014 cr | ₹1,741 cr | 22.13% | 27.08% | 0.07x | 36.44% |
| FY2022 | ₹1,231 cr | ₹406 cr | ₹7.22 | ₹1,619 cr | ₹1,355 cr | 29.93% | 40.04% | 0.03x | 32.94% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.